THERAPY DOSSIER · th-4422e73a1736

Selective C5aR antagonist (C5aR-A)

Drug · Selective C5a receptor (C5aR/CD88) antagonist (unspecified agent); no confident ChEMBL name match

Evidence & regulatory context

Mechanism: Selective C5a receptor (C5aR/CD88) antagonist (unspecified agent); no confident ChEMBL name match
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25904802 ↗2015Mixed findings

The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury.

MouseSpinal cord injuryContusionC5ar knockout and wild-type mice, plus bone marrow chimeric miceAdministered during the first 7 days after injury, or continued into the chroni…

Model: Contusive spinal cord injury

C5aR signalling was injurious acutely but protective or reparative later. C5ar knockout mice initially recovered better but by day 14 onward had worse function, larger lesions, less myelin and more inflammation at 35 days. Antagonist treatment limited to the first 7 days improved recovery through t…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…